These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37171557)

  • 1. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.
    Yanagi Y; Takahashi K; Iida T; Gomi F; Morii J; Kunikane E; Sakamoto T
    Ophthalmol Ther; 2023 Aug; 12(4):2005-2021. PubMed ID: 37171557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
    Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
    BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice.
    Debourdeau E; Beylerian H; Nguyen V; Barthelmes D; Gillies M; Gabrielle PH; Vujosevic S; Otoole L; Puzo M; Creuzot-Garcher C; Wolff B; Daien V;
    Ophthalmol Ther; 2024 Jul; ():. PubMed ID: 38976148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting: A Multicenter Cohort Study in Japan.
    Yoneda K; Takeuchi M; Yasukawa T; Terasaki H; Yamamoto Y; Jujo T; Wakuta M; Matsubara H; Mitamura Y; Kato A; Kondo M; Kimura K; Takagi H; Gomi F; Sakamoto T;
    Ophthalmol Retina; 2023 Oct; 7(10):869-878. PubMed ID: 37295608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Jin KW; Kim JH; Park JY; Park SJ; Park KH; Lee JY; Woo SJ
    Sci Rep; 2021 Jul; 11(1):14623. PubMed ID: 34272419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes.
    Wakuta M; Nomi N; Ogata T; Ota M; Yamashiro C; Hatano M; Yanai R; Tokuda K; Kimura K
    Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1663-1670. PubMed ID: 32436085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration.
    Chen R; Wu B
    Ann Transl Med; 2020 Aug; 8(15):939. PubMed ID: 32953739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.
    Danyliv A; Glanville J; McCool R; Ferreira A; Skelly A; Jacob RP
    Adv Ther; 2017 Mar; 34(3):611-619. PubMed ID: 28188433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison.
    Ohji M; Lanzetta P; Korobelnik JF; Wojciechowski P; Taieb V; Deschaseaux C; Janer D; Tuckmantel C
    Adv Ther; 2020 May; 37(5):2184-2198. PubMed ID: 32222903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes.
    Horner F; Lip PL; Mohammed BR; Fusi-Rubiano W; Gokhale E; Mushtaq B; Chavan R
    Clin Ophthalmol; 2021; 15():1703-1713. PubMed ID: 33935487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration.
    Navarro-Partida J; Altamirano-Vallejo JC; Aceves Franco LA; Gonzalez-Cortes J; Hernandez-Da Mota S; García-Aguirre JG; Azuara-Galindo CD; Castro-Castaneda CR; Armendariz-Borunda J; Santos A
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
    Cohen SY; Dominguez M; Coscas F; Faure C; Baillif S; Oubraham H; Kodjikian L; Weber M;
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):959-969. PubMed ID: 36399178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
    Bressler NM; Veith M; Hamouz J; Ernest J; Zalewski D; Studnička J; Vajas A; Papp A; Vogt G; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Oh I; Jeong H; Kim MY; Woo SJ
    Br J Ophthalmol; 2023 Mar; 107(3):384-391. PubMed ID: 34656987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M; van der Reis MI; Webers CA; Schouten JS
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.